Low-dose combination therapy: The rationalization for an ACE inhibitor and a calcium channel blocker in higher risk patients

Norman M Kaplan

Research output: Contribution to journalArticle

15 Scopus citations

Abstract

As more high-risk hypertensives are treated and the need for more intensive antihypertensive therapy is recognized, combination therapies are increasingly used. For initial therapy, particularly for relatively low-risk patients, low-dose combinations are often appropriate. For those who require additional therapy, higher doses of combinations may provide further efficacy while minimizing dose-dependent side effects of monotherapy, thereby improving adherence to therapy. Those combination agents should provide 24-h control with one daily dose, thereby ensuring protection in the early morning hours. Combining an angiotensin converting enzyme inhibitor and a calcium channel blocker is a rational approach to treating hypertension. Not only does it provide significantly better blood pressure control than individual components used as monotherapy, it also minimizes dose-dependent side effects. Also, combining agents from different classes results in complementary mechanisms of action that provide other cardiovascular protective benefits.

Original languageEnglish (US)
Pages (from-to)8S-11S
JournalAmerican Journal of Hypertension
Volume14
Issue number5 II
DOIs
StatePublished - 2001

Keywords

  • Angiotensin converting enzyme inhibitors
  • Antihypertension therapy
  • Calcium channel blockers

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'Low-dose combination therapy: The rationalization for an ACE inhibitor and a calcium channel blocker in higher risk patients'. Together they form a unique fingerprint.

  • Cite this